Effect of Intravenous Dextrose on PONV in Patients Undergoing Gynecological Laparoscopy

Postoperative Nausea and Vomiting Clinical Trial

Official title:

Research Investigator

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05932160
• Other study ID #: 2023YX104
• Status: Recruiting
• Phase: N/A
• Start date: June 1, 2023
• Est. completion date: December 30, 2023

Study information

• Verified date: November 2023
• Source: Weifang Medical University
• Contact: Jiang Liu, B.S
• Phone: 17667192336
• Email: Time1987fx[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is to explore the relationship between intravenous infusion of dextrose during emergence from anesthesia and the incidence of PONV in patients undergoing gynecology laparoscopy (GL).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 108
• Est. completion date: December 30, 2023
• Est. primary completion date: December 30, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. ASA I or II;

2. Performing gynecologic laparoscopic procedures under general anesthesia;

Exclusion Criteria:

1. age <18 or >75

2. severe hypertension,diabetes mellitus, significant hepatic or renal disease

3. inability to follow protocol

4. refusal to participant

Related Conditions & MeSH terms

• Postoperative Nausea and Vomiting
• Vomiting

Intervention

Other:
• 5% glucose
Patients in the experimental group were infused intravenously with 5% dextrose (500 ml/h) in the PACU.
• lactated ringers
Patients in the control group were infused intravenously with lactated ringers (500 ml/h) in the PACU.

Locations

Country	Name	City	State
China	Jiang Liu	Weifang	Shandong

Sponsors (1)

Lead Sponsor	Collaborator
Weifang Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Postoperative nausea and vomiting	The severity and incidence of PONV at 0.5 hours postoperatively.	Measured at 0.5 hours postoperatively.
Primary	Postoperative nausea and vomiting	The severity and incidence of PONV at 2 hours postoperatively.	Measured at 2 hours postoperatively.
Primary	Postoperative nausea and vomiting	The severity and incidence of PONV at 24 hours postoperatively.	Measured at 24 hours postoperatively.
Secondary	Consumption of postoperative analgesic	Record the type and dosage of postoperative analgesic within 24 hours after surgery.	Approximately 24 hours after surgery.
Secondary	Postoperative pain response	The Visual Analog Score was used to assess pain response at 0.5 hours postoperatively.; The score ranges from 0 (pain free or no pain) to 10 (worst pain).	Measured at 0.5 hours postoperatively.
Secondary	Postoperative pain response	The Visual Analog Score was used to assess pain response at 2 hours postoperatively.; The score ranges from 0 (pain free or no pain) to 10 (worst pain).	Measured at 2 hours postoperatively.
Secondary	Postoperative pain response	The Visual Analog Score was used to assess pain response at 24 hours postoperatively.; The score ranges from 0 (pain free or no pain) to 10 (worst pain).	Measured at 24 hours postoperatively.
Secondary	Recovery time of PACU	Record PACU recovery time in hours. The criteria for discharge from PACU was the achievement of a modified Aldrete score = 9.	Approximately 24 hours after surgery.
Secondary	Consumption of postoperative rescue antiemetic	Record the type and dosage of postoperative rescue antiemetic within 24 hours after surgery.	Approximately 24 hours after surgery.